The active ingredient in SPRAVATO®, an FDA-approved nasal spray to treat adults with treatment-resistant depression (TRD).
You may benefit from adding SPRAVATO® to your existing oral antidepressant if you’re an adult with major depressive disorder (MDD) who has had an inadequate response to two or more oral antidepressants, known as treatment-resistant depression (TRD).
Adults with treatment-resistant depression who were part of a clinical study were given either a nasal esketamine spray or a placebo spray.
Those who added esketamine, the active ingredient in SPRAVATO®, to their oral antidepressant experienced a greater reduction of depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant.*